Xenetic Biosciences Inc

XBIONASDAQ

Trade with Public

Trade with Public

$1.86

-0.005-0.27%

Últ. Act.: Nov 5, 5:04 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Comparar Informe de acciones

Xenetic Biosciences (XBIO) Stock Price Target 2026

See analyst price targets, ratings and recent upgrades and downgrades for Xenetic Biosciences (XBIO) stock.

Analyst Consensus — 1 Analysts

1Hold

# Analysts1

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Xenetic Biosciences Stock

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Apr 9, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Mar 20, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Dec 5, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Nov 22, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—
Aug 20, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Neutral	—

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciencesto Neutral

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) from Neutral to Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciences

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) with a Neutral.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Neutral on Xenetic Biosciences

HC Wainwright & Co. analyst Joseph Pantginis reiterates Xenetic Biosciences (NASDAQ:XBIO) with a Neutral.

Benzinga Newsdesk

Lack Of Catalysts Prompts Analyst To Downgrade Xenetic Biosciences

Vandana Singh